Amicus Therapeutics Inc

Amicus Therapeutics — FY2018 Earnings Presentation

31 slides from Amicus Therapeutics's earnings presentation, Feb 28, 2019

  1. Slide 1: FY18 Financial Results Conference Call & Webcast

    FY18 Financial Results Conference Call & Webcast February 28, 2019

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

  3. Slide 3: Introduction: Rare Disease Day

    Introduction 3 Rare Disease Day – February 28, 2019 Rare Disease Day 2019 is “Bridging Health and Social Care”

  4. Slide 4: Amicus Highlights

    Introduction 4 Amicus Highlights GALAFOLD’S EXTRAORDINARY LAUNCH AT-GAA IN POMPE: POTENTIAL TO LEADING GENE THERAPY PORTFOLIO IN RARE SUCCESS BECOME STANDARD OF CARE METABOLIC DISEASES • 650+ Patients and $91.2M Global Sales in FY18 • Continued Strength of Clinical Data • Pipeline of 14 Gene Therapi

  5. Slide 5: 2019 Key Strategic Priorities

    Introduction 5 2019 Key Strategic Priorities 1 Nearly double annual revenue for Galafold (guidance $160M-$180M) Complete enrollment in AT-GAA Pivotal Study (PROPEL) and 2 report additional Phase 1/2 data Report additional 2-year clinical results in CLN6-Batten disease and 3 complete enrollment in on

  6. Slide 6: Galafold Global Launch

    Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement

  7. Slide 7: Galafold: Precision Medicine for Fabry Disease

    Galafold: Precision Medicine for Fabry Disease 7 Galafold Snapshot (as of December 31, 2018) $91.2M $160-180M One of the Most FY18 Galafold FY19 Global Revenue Galafold Successful Rare Rev. Guidance Disease Launches Geographic 24 Countries with Expansion in Pricing & 2019 Reimbursement 8 Regulatory

  8. Slide 8: Galafold Success and FY19 Revenue Guidance

    Galafold: Precision Medicine for Fabry Disease 8 Galafold Success and FY18 Galafold Revenue Guidance On Track to Nearly DOUBLE Revenue Again and Serve 1,000+ Patients in 2019 $160M-180M Guidance $91.2M $32.6M $36.9M $20.6M $80$21.3M-90M $4.9M $16.7M FY16 FY17 FY18 FY19

  9. Slide 9: Upside Potential: Total Amenable Patient Population

    Galafold: Precision Medicine for Fabry Disease 9 Upside Potential Total Amenable Patient Population (“TAPP”) WORLDWIDE Estimate based on 35% - 50% amenability Diagnosis grows due to newborn screening in U.S. & Japan $1B+ Addressable Market TAPP: 4,700-6,750 Peak Potential Opportunity by 2028 WORLDWI

  10. Slide 10: AT-GAA Novel ERT for Pompe Disease

    AT-GAA Novel ERT for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement

  11. Slide 11: AT-GAA: Breakthrough Therapy Designation

    AT-GAA for Pompe Disease 11 AT-GAA: Breakthrough Therapy Designation U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease (LOPD) BTD Criteria • Intended to treat a serious or life threatening disease or condition • Preliminary clinical evidence indicates drug may demonstrate substantial improv

  12. Slide 12: AT-GAA: 2019 Objectives

    AT-GAA for Pompe Disease 12 AT-GAA: 2019 Objectives Advance AT-GAA for as Many Patients Worldwide as Quickly as Possible  Additional Phase 1/2 Data (up to 24 Months)  Breakthrough Therapy Designation • Enroll PROPEL study (n=100) • Present additional Phase 1/2 data (Cohort 4) • Report natural hist

  13. Slide 13: Gene Therapy Pipeline

    Gene Therapy Pipeline “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  14. Slide 14: Amicus Pipeline

    Amicus Pipeline 14 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) monotherapy Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) Pompe Gene Therapy PENN Batten Franchise – Gene Therapies NCH CLN6 Batten Disease Advancing one NC

  15. Slide 15: Amicus Gene Therapy Programs

    Amicus Gene Therapy Programs 15 Leading LSD Gene Therapy Portfolio Multiple Platforms Provide 14 Gene Therapy Programs and R&D Engine for Future Growth Gene Therapy Anticipated Milestones 2-Year CLN6 Batten Disease Phase 1/2 Data (Mid- 2019) CLN3 Batten Disease Phase 1/2 Study Enrolling CLN8 and CLN

  16. Slide 16: Global Research and Gene Therapy Center of Excellence in Philadelphia

    Amicus Gene Therapy Programs 16 Amicus Global Research and Gene Therapy Center of Excellence in Philadelphia Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company in Burgeoning Hub for Medical Breakthroughs » New 75,000 sqft state-of-the-art facility » Located in uCi

  17. Slide 17: Milestones

    Milestones “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  18. Slide 18: Anticipated Milestones: 2019

    Upcoming Milestones 18 Anticipated Milestones: 2019 Well-Positioned to Create Significant Value for Shareholders and Patients in 2019 Galafold: Fabry Disease AT-GAA: Pompe Disease Gene Therapy Programs • FY19 revenue guidance $160M-  Additional Phase 1/2 data (21 • Ongoing CLN3 Batten disease $180M

  19. Slide 19: A Rare Company: Commercial Organizational Strength

    A Rare Company Commercial Organizational Strength “We are business led and science driven” - Amicus Belief Statement

  20. Slide 20: Global Footprint

    Commercial Organizational Strength 20 Global Footprint Global operations in North America EU place across the largest rare disease markets » employees supporting our global 150+ Galafold business » ~100 in Commercial » ~50 in Medical Affairs » countries with offices, including US, 11 EU5, Japan ROW

  21. Slide 21: Experienced Passionate Commercial Team

    Commercial Organizational Strength 21 Experienced Passionate Commercial Team Proven global capabilities driving Galafold’s extraordinary launch success Diverse Experience in Background Passion for Rare Disease and Patients Drug Launch Experiences Galafold is indicated for adults with a confirmed dia

  22. Slide 22: An Innovative Product

    Commercial Organizational Strength 22 An Innovative Product Novel Mechanism, Precision Medicine, Commercial Execution Product Execution . Differentiated product profile – . Clear launch focus on priority first oral treatment option patient segments . Rapid determination of . Efficient outreach to ke

  23. Slide 23: Market Access

    Commercial Organizational Strength 23 Market Access Our medicines must be fairly priced and broadly accessible.” - Amicus Founding Belief . Proven patient-centric strategy of ensuring fair price and broad accessibility . Rapid, successful reimbursement in global markets . Amicus assist™ patient supp

  24. Slide 24: Financial Summary

    Financial Summary Full Year Ended December 31, 2019 “Maximizing Value for Shareholders is the Foundation for Our Future Successes” - Amicus Belief Statement

  25. Slide 25: FY18 Select Financial Results

    Financial Summary 25 FY18 Select Financial Results FY18 Revenue of $91.2M Primarily from International Galafold Sales Dec. 31, 2018 (in thousands, except per share data) Dec. 31, 2017 Product revenue 91,245 36,930 Cost of goods sold 14,404 6,236 R&D expense 270,902* 149,310 SG&A expense 127,200 88,6

  26. Slide 26: Financial Summary and Guidance

    Financial Summary 26 Financial Summary and Guidance Strong Balance Sheet with $500M+ Cash at 12/31/18 - Cash Runway into 2021 FINANCIAL POSITION December 31, 2018 Cash ~$504M Cash Runway Into at least mid-2021 CAPITALIZATION Shares Outstanding 189,383,924 FINANCIAL GUIDANCE Projected YE 2019 Cash Ba

  27. Slide 27: Closing: Impacting Lives

    Closing 27 Impacting Lives >350 Patients* | ~$36M Global Sales >700 Patients* | ~$91M1 Global Sales 5,000 Patients* | $1B Global Sales YE17 YE18 2023 *Clinical & commercial, all figures approximate 1Preliminary unaudited

  28. Slide 28: Appendix

    Appendix

  29. Slide 29: Pompe Patient Experience in Phase 1/2 Clinical Study

    AT-GAA for Pompe Disease 29 Pompe Patient Experience in Phase 1/2 Clinical Study (ATB200-02) Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers in both ERT-Switch and ERT-Naïve Pompe Patients out to Month 18 6-Minute Walk Test (m) Change at Month 24a,b

  30. Slide 30: PROPEL (ATB200-03) Study Design

    AT-GAA for Pompe Disease 30 PROPEL (ATB200-03) Study Design 52-Week Primary Treatment Period Long-Term Extension (Double-Blind) (Open-Label) Participants with Late-Onset AT-GAA Pompe Disease Bi-Weekly ~100 Patients AT-GAA 90 Clinical Sites Worldwide Bi-weekly Standard of Care ERT-Switch ERT-Naïve Bi

  31. Slide 31: Thank You

    Thank You “Our passion for making a difference unites us” -Amicus Belief Statement

Amicus Therapeutics — FY2018 Earnings Presentation on 6ix